ApicHope Pharmaceutical Group Co., Ltd. (SHE:300723)

Market Cap	15.57B -3.3%
Revenue (ttm)	940.78M -21.9%
Net Income	199.99M
EPS	0.44
Shares Out	448.53M
PE Ratio	78.40
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,474,800
Open	39.86
Previous Close	34.71
Day's Range	34.30 - 39.86
52-Week Range	29.31 - 81.48
Beta	0.68
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 24, 2026

About SHE:300723

ApicHope Pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of pharmaceutical drugs in China. The company offers pediatric medicines, such as fuganlin and yiqi jianpi oral liquids, carboxymestrine oral solutions, and xiao’er kechuanling oral liquid products; and clindamycin palmitate hydrochloride dispersible tablets, acetylkitasamycin for suspension, qinxiangqingjie oral liquids, epinastine hydrochloride granules, clindamycin palmitate hydrochloride granules, clindamyxin hydrochloride for injection, clind...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 1,294
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300723

Financial Performance

In 2025, SHE:300723's revenue was 932.27 million, a decrease of -35.72% compared to the previous year's 1.45 billion. Losses were -337.79 million, -37.45% less than in 2024.